1.
|
I
have reviewed the annual filings (as this term is defined in Multilateral
Instrument 52-109 Certification of Disclosure in Issuers’ Annual and
Interim Filings) of Lorus Therapeutics Inc., (the issuer) for the
period ending May 31,
2007;
|
2.
|
Based
on my knowledge, the annual filings do not contain any untrue statement
of
a material fact or omit to state a material fact required to be
stated or
that is necessary to make a statement not misleading in light of
the
circumstances under which it was made, with respect to the period
covered
by the annual filings;
|
3.
|
Based
on my knowledge, the annual financial statements together with
the other
financial information included in the annual filings fairly present
in all
material respects the financial condition, results of operations
and cash
flows of the issuer, as of the date and for the periods presented
in the
annual filings;
|
4.
|
The
issuer’s other certifying officers and I are responsible for establishing
and maintaining disclosure controls and procedures and internal
control
over financial reporting for the issuer, and we
have:
|
|
(a)
|
designed
such disclosure controls and procedures, or caused them to be designed
under our supervision, to provide reasonable assurance that material
information relating to the issuer, including its consolidated
subsidiaries, is made known to us by others within those entities,
particularly during the period in which the annual filings are
being
prepared;
|
|
(b)
|
designed
such internal control over financial reporting, or caused it to
be
designed under our supervision, to provide reasonable assurance
regarding
the reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with the issuer’s GAAP;
and
|
|
(c)
|
evaluated
the effectiveness of the issuer’s disclosure controls and procedures as of
the end of the period covered by the annual filings and have caused
the
issuer to disclose in the annual MD&A our conclusions about the
effectiveness of the disclosure controls and procedures as of the
end of
the period covered by the annual filings based on such
evaluation;
|
5.
|
I
have caused the issuer to disclose in the annual MD&A any change in
the issuer’s internal control over financial reporting that occurred
during the issuer’s most recent interim period that has materially
affected, or is reasonably likely to materially affect, the issuer’s
internal control over financial
reporting.
|
Date:
August 29, 2007.
|
|
/s/
Aiping Young
|
1.
|
I
have reviewed the annual filings (as this term is defined in
Multilateral
Instrument 52-109 Certification of Disclosure in Issuers’ Annual and
Interim Filings) of Lorus Therapeutics Inc., (the issuer) for the
period ending May 31,
2007;
|
2.
|
Based
on my knowledge, the annual filings do not contain any untrue
statement of
a material fact or omit to state a material fact required to
be stated or
that is necessary to make a statement not misleading in light
of the
circumstances under which it was made, with respect to the period
covered
by the annual filings;
|
3.
|
Based
on my knowledge, the annual financial statements together with
the other
financial information included in the annual filings fairly present
in all
material respects the financial condition, results of operations
and cash
flows of the issuer, as of the date and for the periods presented
in the
annual filings;
|
4.
|
The
issuer’s other certifying officers and I are responsible for establishing
and maintaining disclosure controls and procedures and internal
control
over financial reporting for the issuer, and we
have:
|
|
(a)
|
designed
such disclosure controls and procedures, or caused them to be
designed
under our supervision, to provide reasonable assurance that material
information relating to the issuer, including its consolidated
subsidiaries, is made known to us by others within those entities,
particularly during the period in which the annual filings are
being
prepared;
|
|
(b)
|
designed
such internal control over financial reporting, or caused it
to be
designed under our supervision, to provide reasonable assurance
regarding
the reliability of financial reporting and the preparation of
financial
statements for external purposes in accordance with the issuer’s GAAP;
and
|
|
(c)
|
evaluated
the effectiveness of the issuer’s disclosure controls and procedures as of
the end of the period covered by the annual filings and have
caused the
issuer to disclose in the annual MD&A our conclusions about the
effectiveness of the disclosure controls and procedures as of
the end of
the period covered by the annual filings based on such
evaluation;
|
5.
|
I
have caused the issuer to disclose in the annual MD&A any change in
the issuer’s internal control over financial reporting that occurred
during the issuer’s most recent interim period that has materially
affected, or is reasonably likely to materially affect, the issuer’s
internal control over financial
reporting.
|
Date:
August
29, 2007.
|
|
/s/
Elizabeth Williams
|